Literature DB >> 29061244

Neuromyelitis Optica.

Sarah L Patterson1, Sarah E Goglin2.   

Abstract

Neuromyelitis optica (NMO), formerly known as Devic disease, is an autoimmune astrocytopathic disease characterized by transverse myelitis and optic neuritis. Most patients demonstrate a relapsing course with incomplete recovery between attacks, resulting in progressive disability. The pathogenesis involves production of aquaporin-4 antibodies (AQP4-IgG) by plasmablasts in peripheral circulation, disruption of the blood-brain barrier, complement-mediated astrocyte injury, and secondary demyelination. The diagnosis relies on characteristic clinical manifestations in the presence of serum AQP4-IgG positivity or specific neuroimaging findings, and exclusion of alternative etiologies. Current treatment involves aggressive immunosuppression with pulse-dose steroids during acute attacks and long-term immunosuppression for attack prevention.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aquaporin-4; Area postrema syndrome; Longitudinally extensive transverse myelitis; Neuromyelitis optica; Optic neuritis

Mesh:

Year:  2017        PMID: 29061244     DOI: 10.1016/j.rdc.2017.06.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  10 in total

1.  Striking neurologic 18F-FDG PET/CT pattern in Devic's disease (neuromyelitis optica spectrum disorder).

Authors:  Diego Alfonso López-Mora; Albert Flotats; Alejandro Fernández; Marina Sizova; Valle Camacho; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-27       Impact factor: 9.236

Review 2.  Ocular manifestations in celiac disease: an overview.

Authors:  Fotios S Fousekis; Andreas Katsanos; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Int Ophthalmol       Date:  2020-01-08       Impact factor: 2.031

3.  Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies.

Authors:  Patrick Murtagh; Amy Coman; Kirk Stephenson; Maria Gaughan; David Ryan; Graeme McNeill; Christopher McGuigan; Lorraine Cassidy
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

4.  A Rare Case of Neuromyelitis Optica Spectrum Disorders With Unknown Fever and Subacute Cognitive Decline With Normal Images.

Authors:  Kento Furuya; Naoya Itoh
Journal:  Cureus       Date:  2022-05-12

Review 5.  Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab.

Authors:  Ava Diarra; Guillaume Gantois; Mouna Lazrek; Basile Verdier; Vincent Elsermans; Hélène Zephir; Benjamin Longère; Xristos Gkizas; Céline Goeminne; Gilles Lemesle; Francis Juthier; Johana Bene; David Launay; Romain Dubois; Sandrine Morell-Dubois; Fanny Vuotto; Anne-Laure Piton
Journal:  Card Fail Rev       Date:  2021-05-12

Review 6.  Experimental Models of Neuroimmunological Disorders: A Review.

Authors:  Ana Paula Bornes da Silva; Rodrigo Braccini Madeira Silva; Leise Daniele Sckenal Goi; Rachel Dias Molina; Denise Cantarelli Machado; Douglas Kazutoshi Sato
Journal:  Front Neurol       Date:  2020-05-12       Impact factor: 4.003

7.  Abnormal Baseline Brain Activity in Neuromyelitis Optica Patients Without Brain Lesion Detected by Resting-State Functional Magnetic Resonance Imaging.

Authors:  Yi Liu; Hua Xiong; Xiaojiao Li; Dan Zhang; Chao Yang; Jiayi Yu; Ruikun Liao; Bi Zhou; Xianlong Huang; Zhuoyue Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-08       Impact factor: 2.570

Review 8.  Involvement of Aquaporins in the Pathogenesis, Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Muhammad Shahnawaz Soyfoo; Clara Chivasso; Jason Perret; Christine Delporte
Journal:  Int J Mol Sci       Date:  2018-10-30       Impact factor: 5.923

Review 9.  Novel Molecular Leads for the Prevention of Damage and the Promotion of Repair in Neuroimmunological Disease.

Authors:  Mahshad Kolahdouzan; Naomi C Futhey; Nicholas W Kieran; Luke M Healy
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

Review 10.  Cognitive impairment in NMOSD-More questions than answers.

Authors:  Dominika Czarnecka; Magdalena Oset; Iwona Karlińska; Mariusz Stasiołek
Journal:  Brain Behav       Date:  2020-10-06       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.